Tif-1 antibody

TIF-1 (p155/140) antibodies (TIF= acronym for "transcriptional intermediary factor 1 gamma") are disease-specific and correlate strongly with malignancy. TIF-1gamma is a protein involved in the inhibition of tumorigenesis and metastasis in various malignancies, including breast cancer.

TIF-1 (p155/140) antibody is detected in 40-75% of cases of paraneoplastic dermatomyositis, 20-25% of cases of the classic adult form and about 30% of cases of juvenile dermatomyositis.

In tumor-associated dermatomyositis, the clinical symptoms may be due to a cross-reactive immune response directed against tumor-associated antigens on cancer cells as well as against constitutive antigens in skin and muscle tissue. The appearance of neoantigens due to loss of heterozygosity or mutations in TIF-1-gamma alleles in malignant cells may lead to autoimmunity and thus promote the production of anti-TIF-1-gamma antibodies that cross-react with corresponding TIF-1 antigens in skin and muscle. It is postulated that the serum level of anti-TIF-1-gamma autoantibodies positively correlates with disease activity (Wang WY et al. 2024).

1. Volc-Platzer B (2015) Dermatomyositis update. Dermatology 66:604-610
2. Wang WY et al (2024) Anti-TIF-a-gamma associated dermatomyositis in recurrent triple-negative breast cancer. JDDG 20: 1008-1012